Literature DB >> 7912124

Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region.

N Drakoulis1, I Cascorbi, J Brockmöller, C R Gross, I Roots.   

Abstract

Genetic differences in the metabolism of carcinogens may codetermine individual predisposition to cancer. Cytochrome P-4501A1 (CYP1A1) metabolically activates precarcinogens in cigarette smoke, such as benzo(a)pyrene, which is also an inducer of CYP1A1. Two point mutations have been reported, m1 in the 3'-flanking region (6235T to C), and m2 within exon 7 (4889A to G), the latter leading to an isoleucine to valine exchange. In the Japanese population m1 and m2 are correlated with lung cancer, suggesting an increased susceptibility to cigarette smoking related lung cancer. We studied 142 lung cancer and 171 reference patients in an ethnically homogeneous German group for m1 and m2 mutations by restriction fragment length polymorphism and allele-specific polymerase chain reaction, respectively. No statistically significant difference was found in the distribution of m1 alleles between lung cancer and controls; the frequency was 8.5% and 7.3% of the alleles, respectively (odds ratio = 1.17). A trend to an overrepresentation of m1 alleles was observed among 52 squamous cell carcinoma patients (odds ratio = 1.65). In contrast, the frequency of m2 alleles in lung cancer patients was twofold higher (6.7%) than in the reference group (3.2%; odds ratio = 2.16; 95% confidence limits 0.96-5.11, P = 0.033); the odds ratio of m2 alleles in squamous cell carcinoma was 2.51 (95% confidence limits 0.85-7.05, P = 0.05). There was a close genetic linkage of m2 to m1 (10 of 11 reference patients), but a significantly higher number of cancer patients showed no linkage compared to the controls (odds ratio = 8.89, 95% confidence limits 0.83-433, P = 0.04).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912124     DOI: 10.1007/bf00189321

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  24 in total

1.  Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene.

Authors:  K Kawajiri; K Nakachi; K Imai; A Yoshii; N Shinoda; J Watanabe
Journal:  FEBS Lett       Date:  1990-04-09       Impact factor: 4.124

2.  Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene.

Authors:  S Hayashi; J Watanabe; K Nakachi; K Kawajiri
Journal:  J Biochem       Date:  1991-09       Impact factor: 3.387

3.  Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose.

Authors:  K Nakachi; K Imai; S Hayashi; J Watanabe; K Kawajiri
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

Review 4.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes.

Authors:  F P Guengerich; T Shimada
Journal:  Chem Res Toxicol       Date:  1991 Jul-Aug       Impact factor: 3.739

5.  Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism.

Authors:  A K Jaiswal; F J Gonzalez; D W Nebert
Journal:  Nucleic Acids Res       Date:  1985-06-25       Impact factor: 16.971

Review 6.  Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin.

Authors:  D W Nebert; D D Petersen; A Puga
Journal:  Pharmacogenetics       Date:  1991-11

7.  Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes.

Authors:  R E Kouri; C E McKinney; D J Slomiany; D R Snodgrass; N P Wray; T L McLemore
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

8.  Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.

Authors:  A Hirvonen; K Husgafvel-Pursiainen; S Anttila; A Karjalainen; M Sorsa; H Vainio
Journal:  Pharmacogenetics       Date:  1992-12

9.  Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.

Authors:  K L Rost; H Brösicke; J Brockmöller; M Scheffler; H Helge; I Roots
Journal:  Clin Pharmacol Ther       Date:  1992-08       Impact factor: 6.875

10.  Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism.

Authors:  P G Shields; H Sugimura; N E Caporaso; S F Petruzzelli; E D Bowman; B F Trump; A Weston; C C Harris
Journal:  Environ Health Perspect       Date:  1992-11       Impact factor: 9.031

View more
  17 in total

1.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

2.  Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population.

Authors:  R C Sobti; S Sharma; A Joshi; S K Jindal; A Janmeja
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

3.  Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study.

Authors:  M L Cote; A S Wenzlaff; C H Bock; S J Land; S K Santer; D R Schwartz; A G Schwartz
Journal:  Lung Cancer       Date:  2006-12-15       Impact factor: 5.705

4.  Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer.

Authors:  João Paulo Souto Grando; Hellen Kuasne; Roberta Losi-Guembarovski; Iara Sant'ana Rodrigues; Henrique Mitsu Matsuda; Paulo Emílio Fuganti; Emerson Pereira Gregório; Farid Libos Júnior; Rodrigo Paes de Menezes; Marco Aurélio de Freitas Rodrigues; Ilce Mara de Syllos Cólus
Journal:  Clin Exp Med       Date:  2008-11-01       Impact factor: 3.984

Review 5.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

6.  Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer.

Authors:  Chikako Kiyohara; Taro Shirakawa; Julian M Hopkin
Journal:  Environ Health Prev Med       Date:  2002-05       Impact factor: 3.674

7.  A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.

Authors:  Yoshihiro Isomura; Yutaka Yamaji; Miki Ohta; Motoko Seto; Yoshinari Asaoka; Yasuo Tanaka; Takashi Sasaki; Yousuke Nakai; Naoki Sasahira; Hiroyuki Isayama; Minoru Tada; Haruhiko Yoshida; Takao Kawabe; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2010-06-12       Impact factor: 7.527

8.  p53 gene mutations, and CYP1A1 and GSTM1 genotypes in pulmonary squamous cell carcinomas.

Authors:  S Ohshima; Y Xu
Journal:  Mol Pathol       Date:  1997-04

9.  Mitogen-activated lymphocytes: a good model for characterising lung CYP1A1 inducibility.

Authors:  M Jacquet; V Lambert; A Todaro; P Kremers
Journal:  Eur J Epidemiol       Date:  1997-02       Impact factor: 8.082

10.  Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

Authors:  Michele L Cote; Wonsuk Yoo; Angela S Wenzlaff; Geoffrey M Prysak; Susan K Santer; Gina B Claeys; Alison L Van Dyke; Susan J Land; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2009-01-27       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.